Transdermal pharmaceutical composition comprising Zolpidem

The invention relates to transdermal pharmaceutical compositions containing an imidazo [1,2- a ] pyridine-3-acetamide such as Zolpidem. Compositions comprising an imidazo [1,2- a ] pyridine-3-acetamide and caffeine are also disclosed. Claims to the compositions for treating disorders including leukoencephalopathy, obsessive compulsive disorder, brain lesions, cerebral infarct, intracerebral bleeding, Ramsay-Hunt syndrome, ischemic brain damage; and conditions involving strabismus, salivation, muscle spasm, impaired swallowing, smell, or taste, are also included. A further independent claim is included for a composition comprising an imidazo [1,2- a ] pyridine-3-acetamide and caffeine.